Cargando…
Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target
INTRODUCTION: IGF2BP3 (IMP3) is a mRNA binding protein that regulates IGF2 translation and function during embryogenesis. Because IGF2BP3 is undetectable in adult human tissues except the testis, and increased IGF2BP3 expression has been noted in several cancers, it is considered a cancer testis (CT...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506364/ https://www.ncbi.nlm.nih.gov/pubmed/26244168 |
_version_ | 1782381668441522176 |
---|---|
author | Shantha Kumara, HMC Kirchoff, Daniel Caballero, Otavia L. Su, Tao Ahmed, Aqeel Herath, Sonali AC. Njoh, Linda Cekic, Vesna Simpson, Andrew J. Cordon-Cardo, Carlos Whelan, Richard L. |
author_facet | Shantha Kumara, HMC Kirchoff, Daniel Caballero, Otavia L. Su, Tao Ahmed, Aqeel Herath, Sonali AC. Njoh, Linda Cekic, Vesna Simpson, Andrew J. Cordon-Cardo, Carlos Whelan, Richard L. |
author_sort | Shantha Kumara, HMC |
collection | PubMed |
description | INTRODUCTION: IGF2BP3 (IMP3) is a mRNA binding protein that regulates IGF2 translation and function during embryogenesis. Because IGF2BP3 is undetectable in adult human tissues except the testis, and increased IGF2BP3 expression has been noted in several cancers, it is considered a cancer testis (CT) protein. IGF2BP3 mRNA expression in colorectal cancers (CRC) has not been well studied. This study's aim was to quantitatively assess IGF2BP3 mRNA expression in CRC and, thus, determine if IGF2BP3 has potential as a vaccine target. METHOD: Data were collected prospectively from CRC patients in an IRB-approved tissue and data bank. Total RNA was isolated and purified from tumor and normal colonic tissue samples and cDNA synthesized. IGF2BP3 expression was analyzed by quantitative PCR (QPCR). Expression levels of IGF2BP3 in tumors and testis were determined and compared. Tumors with levels greater than 0.1% or more of the testis levels were considered positive. Analysis of IGF2BP3 protein expression by immunohistochemistry (IHC) in tumor and normal tissues was also performed. RESULTS: A total of 84 paired tumor and normal tissue specimens were assessed from patients with Stage 2 and 3 CRC; 43% of tumors had IGF2BP3 mRNA expression levels greater than 0.1 % of that of testis and were considered positive. The median tumor expression level was higher in women (p=0.042). No correlation was found between IGF2BP3 mRNA expression and tumor stage or lymph node involvement. IHC was carried out on paired tumor and normal tissue sections from 46 patients; IGF2BP3 staining was noted in 50% of the tumor sections and in 5% of the normal tissue sections. DISCUSSION: IGF2BP3 mRNA was over expressed in 43% of the tumors whereas the protein was noted in 50% of samples. No correlation between mRNA expression and disease severity was noted. This protein holds promise as a vaccine target, however, a larger study that assesses a more diverse population of patients (Stage 1-4) as well as a study of preoperative serum samples for auto-antibodies to IGF2BP3 are needed to pursue this concept. |
format | Online Article Text |
id | pubmed-4506364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-45063642015-08-04 Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target Shantha Kumara, HMC Kirchoff, Daniel Caballero, Otavia L. Su, Tao Ahmed, Aqeel Herath, Sonali AC. Njoh, Linda Cekic, Vesna Simpson, Andrew J. Cordon-Cardo, Carlos Whelan, Richard L. Oncoscience Research Paper INTRODUCTION: IGF2BP3 (IMP3) is a mRNA binding protein that regulates IGF2 translation and function during embryogenesis. Because IGF2BP3 is undetectable in adult human tissues except the testis, and increased IGF2BP3 expression has been noted in several cancers, it is considered a cancer testis (CT) protein. IGF2BP3 mRNA expression in colorectal cancers (CRC) has not been well studied. This study's aim was to quantitatively assess IGF2BP3 mRNA expression in CRC and, thus, determine if IGF2BP3 has potential as a vaccine target. METHOD: Data were collected prospectively from CRC patients in an IRB-approved tissue and data bank. Total RNA was isolated and purified from tumor and normal colonic tissue samples and cDNA synthesized. IGF2BP3 expression was analyzed by quantitative PCR (QPCR). Expression levels of IGF2BP3 in tumors and testis were determined and compared. Tumors with levels greater than 0.1% or more of the testis levels were considered positive. Analysis of IGF2BP3 protein expression by immunohistochemistry (IHC) in tumor and normal tissues was also performed. RESULTS: A total of 84 paired tumor and normal tissue specimens were assessed from patients with Stage 2 and 3 CRC; 43% of tumors had IGF2BP3 mRNA expression levels greater than 0.1 % of that of testis and were considered positive. The median tumor expression level was higher in women (p=0.042). No correlation was found between IGF2BP3 mRNA expression and tumor stage or lymph node involvement. IHC was carried out on paired tumor and normal tissue sections from 46 patients; IGF2BP3 staining was noted in 50% of the tumor sections and in 5% of the normal tissue sections. DISCUSSION: IGF2BP3 mRNA was over expressed in 43% of the tumors whereas the protein was noted in 50% of samples. No correlation between mRNA expression and disease severity was noted. This protein holds promise as a vaccine target, however, a larger study that assesses a more diverse population of patients (Stage 1-4) as well as a study of preoperative serum samples for auto-antibodies to IGF2BP3 are needed to pursue this concept. Impact Journals LLC 2015-07-01 /pmc/articles/PMC4506364/ /pubmed/26244168 Text en Copyright: © 2015 Shantha Kumara et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shantha Kumara, HMC Kirchoff, Daniel Caballero, Otavia L. Su, Tao Ahmed, Aqeel Herath, Sonali AC. Njoh, Linda Cekic, Vesna Simpson, Andrew J. Cordon-Cardo, Carlos Whelan, Richard L. Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title | Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title_full | Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title_fullStr | Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title_full_unstemmed | Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title_short | Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target |
title_sort | expression of the cancer testis antigen igf2bp3 in colorectal cancers; igf2bp3 holds promise as a specific immunotherapy target |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506364/ https://www.ncbi.nlm.nih.gov/pubmed/26244168 |
work_keys_str_mv | AT shanthakumarahmc expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT kirchoffdaniel expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT caballerootavial expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT sutao expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT ahmedaqeel expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT herathsonaliac expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT njohlinda expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT cekicvesna expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT simpsonandrewj expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT cordoncardocarlos expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget AT whelanrichardl expressionofthecancertestisantigenigf2bp3incolorectalcancersigf2bp3holdspromiseasaspecificimmunotherapytarget |